within Pharmacolibrary.Drugs.ATC.G;

model G03XC02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.06,
    Cl             = 6.666666666666667e-06,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.014199999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011666666666666665,
    Tlag           = 19.8
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G03XC02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Bazedoxifene is a selective estrogen receptor modulator (SERM) used primarily in the prevention and treatment of postmenopausal osteoporosis. It is approved for clinical use in several countries and is often combined with conjugated estrogens for management of menopausal symptoms, but its use is most established in osteoporosis prevention.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy postmenopausal women following single oral administration.</p><h4>References</h4><ol><li><p>McKeand, W (2017). Pharmacokinetics, Dose Proportionality, and Bioavailability of Bazedoxifene in Healthy Postmenopausal Women. <i>Clinical therapeutics</i> 39(9) 1769–1779. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2017.07.012\">10.1016/j.clinthera.2017.07.012</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28756067/\">https://pubmed.ncbi.nlm.nih.gov/28756067</a></p></li><li><p> (2019). Estradiol/progesterone (Bijuva) for menopausal vasomotor symptoms. <i>The Medical letter on drugs and therapeutics</i> 61(1575) 99–101. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31381541/\">https://pubmed.ncbi.nlm.nih.gov/31381541</a></p></li><li><p>McKeand, W, et al., &amp; Korth-Bradley, J (2018). Assessment of the Effects of Age and Renal Function on Pharmacokinetics of Bazedoxifene in Postmenopausal Women. <i>Clinical pharmacology in drug development</i> 7(8) 920–926. DOI:<a href=\"https://doi.org/10.1002/cpdd.607\">10.1002/cpdd.607</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30144296/\">https://pubmed.ncbi.nlm.nih.gov/30144296</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G03XC02;
